Adjuvant Therapy News and Research RSS Feed - Adjuvant Therapy News and Research

Adjuvant Therapy is treatment given after the primary treatment to increase the chances of a cure. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, or biological therapy.
ASTRO clinical practice statement outlines recommendations to customize treatment for rectal cancer

ASTRO clinical practice statement outlines recommendations to customize treatment for rectal cancer

The American Society for Radiation Oncology recently issued a new clinical practice statement, "Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement Using the RAND/UCLA Appropriateness Method." [More]
Study finds low rates of baseline BMD testing among older women with breast cancer

Study finds low rates of baseline BMD testing among older women with breast cancer

Aromatase inhibitors (AIs)—drugs that stop the production of estrogen in women—are standard adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer. [More]
Whole-genome omics data can improve accuracy of breast cancer survival predictions

Whole-genome omics data can improve accuracy of breast cancer survival predictions

Precise predictions of whether a tumor is likely to spread would help clinicians and patients choose the best course of treatment. But current methods fall short of the precision needed. [More]
Itaconate can suppress pro-inflammatory activity of macrophages

Itaconate can suppress pro-inflammatory activity of macrophages

An international group of scientists from US, Canada, Germany and Russia has revealed a substance produced in humans that can suppress the pro-inflammatory activity of macrophages - specific cells of immune system. [More]
Researchers identify lymphatic endothelial lineage that shows potential for new anti-cancer treatment

Researchers identify lymphatic endothelial lineage that shows potential for new anti-cancer treatment

Identifying the cell of origin is crucial to understanding how a tumor develops and metastasizes and for developing targeted therapies. [More]
STING agonists developed to induce cellular death in B cell malignancies

STING agonists developed to induce cellular death in B cell malignancies

In almost every mammalian cell, you will find the endoplasmic reticulum, a network of continuous membranes responsible for controlling metabolism as well as the folding, assembly and secretion of proteins. [More]
Beta blockers may improve effectiveness of triple negative breast cancer treatments

Beta blockers may improve effectiveness of triple negative breast cancer treatments

New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor. [More]
Researchers discover new biomarker that puts patients at higher risk for metastasis of uveal melanoma

Researchers discover new biomarker that puts patients at higher risk for metastasis of uveal melanoma

A study by J. William Harbour, M.D., associate director for Basic Research and leader of the Eye Cancer Site Disease Group at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and colleagues published today in Clinical Cancer Research details the discovery of a biomarker that puts patients at a higher risk for metastasis of uveal melanoma. [More]
Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Chemotherapy better than chemoradiotherapy in reducing distant pancreatic cancer recurrences

Patients who received chemotherapy after surgical resection of pancreatic cancer have fewer distant disease recurrences and longer overall survival than those who also had adjuvant chemoradiation therapy. [More]
Most stage III melanoma patients do not benefit from interferon treatment

Most stage III melanoma patients do not benefit from interferon treatment

Final results for the Sunbelt Melanoma Trial, published online this month in the Journal of Clinical Oncology, show that thanks to current diagnostic techniques, most stage III melanoma patients do not benefit from treatment with interferon. [More]
New research identifies key enzyme linked to age-related increases in cancer and inflammation

New research identifies key enzyme linked to age-related increases in cancer and inflammation

For the first time, researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration, according to new research from the Perelman School of Medicine at the University of Pennsylvania. [More]
ACS, Alliance begin work on second volume of manual for cancer surgery

ACS, Alliance begin work on second volume of manual for cancer surgery

The American College of Surgeons and the Alliance for Clinical Trials in Oncology announced that they have begun work on the second volume of a comprehensive, evidence-based examination of cancer surgery techniques and recommendations. [More]
Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Treatment with the chemotherapy agent capecitabine increased disease-free survival for women with HER2-negative breast cancer that was not eliminated by presurgery chemotherapy, according to results from the phase III CREATE-X clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. [More]
Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing chemotherapy may increase risk of death for triple-negative breast cancer patients

Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer (TNBC), according to a new study from The University of Texas MD Anderson Cancer Center. [More]
Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Monoclonal antibody reduces relapse rate by 18% in postmenopausal, HR-positive breast cancer patients

Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival. [More]
TGen: PPF drug could help treat patients with deadly brain cancer

TGen: PPF drug could help treat patients with deadly brain cancer

In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer. [More]
Study explores benefits of breast cancer adjuvant therapies

Study explores benefits of breast cancer adjuvant therapies

After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true. [More]
Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Yervoy approved for patients at high risk of developing recurrence of melanoma after surgery

Today the U.S. Food and Drug Administration expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. [More]
Caring for women who develop invasive breast tumor in Germany

Caring for women who develop invasive breast tumor in Germany

Every year, more than 70 000 women in Germany develop an invasive breast tumor. This makes breast cancer the most common tumor disease in women. The current edition of Deutsches Ärzteblatt International (Edition 35/36) contains no less than three articles focusing on breast cancer. [More]
EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

EORTC trial evaluates effectiveness of pembrolizumab in patients with high-risk stage III melanoma

A recently opened double- blind phase III EORTC trial 1325 will prospectively assess whether post-operative adjuvant therapy with pembrolizumab, an anti-PD-1 monoclonal antibody, improves recurrence-free survival as compared to placebo in patients with high-risk stage III melanoma. [More]
Advertisement
Advertisement